Saving lives through innovation
Genexine is a leading biopharmaceutical company focused on discovering, developing and commercializing first and best-in-class immunotherapies for cancer and antibody therapies for rare diseases. With its headquarters located in Seoul South Korea, Genexine is currently undergoing a transformation to be the first Korean biopharmaceutical company to expand onto the global stage.
Genexine’s pipeline of innovative medicines is built upon two proprietary technologies, hyFc® and DNA vaccine platforms. The hyFc® platform technology is used for development of long-acting protein drugs, maximizing the half-life of drugs in the human body through fusion with various drugs. A second proprietary platform technology developed by Genexine is its DNA vaccine platform. The platform inserts a genetic fragment involved in protein production into a vaccine, eliciting immune responses in the human body to fight viral infection and cancer cells.
As a part of the company’s transition to becoming a commercial stage, global company, Neil Warma was appointed as President&CEO in 2022. He has outlined his vision for commercializing Genexine’s first products and expanding into the North American and global market. In May 2022, Genexine moved to its new headquarters, “Genexine-ProGen Bio Innovation Park” in South Korea’s world-class technology park in Magok, Seoul to strengthen its research capabilities in a strong R&D-focused environment.
Vision to be Global Bio Leader by 2030
With 22 years of history, Genexine is now focusing its efforts on becoming a leading, global biopharmaceutical company by 2030. The company has built a solid scientific foundation for growth through strong R&D, CMC and development capabilities. It is now poised to expand beyond the Korean borders to complement its drug development efforts on a global scale. Genexine’s goal is to become the first Korean global biopharmaceutical company.
Expanding beyond Korea will enable Genexine to broaden its access to technology, markets and expertise. Genexine is unique in that it has access to a strong talent base and technology in Korea and will soon be able to expand and access similar in the U.S. and globally.
based on our core values
Our dream is to develop medicines to improve and save the lives of patients around the world. In doing so, we remain dedicated and passionate in all our endeavors and strongly believe in a culture of collaboration, growth and the development of both the corporation and the individual.
We strive to deliver the best outcomes for our patients with passion and commitment.
We strive to maintain a high level of integrity and credibility with all of our stakeholders through open communication, transparency and honesty.
We believe in having a positive attitude in all that we do to proactively bring about change and efficiently attain our ambitious goals.